Cargando…

Analysis of β-agonists in Different Biological Matrices By Liquid Chromatography–tandem Mass Spectrometry

INTRODUCTION: Wide use is made of β-agonists in therapy due to their smooth muscle–relaxant properties. They also have a side effect of increasing muscle mass. Besides improving oxygen utilisation as bronchodilators, β-agonists increase protein synthesis and promote fat burning. The growth- and perf...

Descripción completa

Detalles Bibliográficos
Autores principales: Śniegocki, Tomasz, Sell, Bartosz, Posyniak, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775736/
https://www.ncbi.nlm.nih.gov/pubmed/35112001
http://dx.doi.org/10.2478/jvetres-2021-0058
_version_ 1784636659521814528
author Śniegocki, Tomasz
Sell, Bartosz
Posyniak, Andrzej
author_facet Śniegocki, Tomasz
Sell, Bartosz
Posyniak, Andrzej
author_sort Śniegocki, Tomasz
collection PubMed
description INTRODUCTION: Wide use is made of β-agonists in therapy due to their smooth muscle–relaxant properties. They also have a side effect of increasing muscle mass. Besides improving oxygen utilisation as bronchodilators, β-agonists increase protein synthesis and promote fat burning. The growth- and performance-enhancing effects are often exploited in illegal use. The guiding objective of this study was to develop a procedure for the determination of β-agonists by a single method in different types of matrices. MATERIAL AND METHODS: Five grams of homogenised samples were subjected to enzymatic hydrolysis with β-glucuronidase in ammonium acetate, pH 5.2. Purification was performed by solid phase extraction. Analytes were eluted with 10% acetic acid in methanol. The eluted β-agonists were analysed by high-performance liquid chromatography–tandem mass spectrometry. RESULTS: Validation results met the requirement of the confirmation criteria according to European Commission Decision 2002/657/EC in terms of apparent recoveries (93.2–112.0%), repeatability (3.1–7.1%) and intra-laboratory reproducibility (4.1–8.2%). CONCLUSION: The method can be successfully applied in the detection and determination of clenbuterol, salbutamol, mabuterol, mapenterol, terbutaline, brombuterol, zilpaterol, isoxsuprine and ractopamine in feed, drinking water, urine, muscle, lung and liver matrices.
format Online
Article
Text
id pubmed-8775736
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Sciendo
record_format MEDLINE/PubMed
spelling pubmed-87757362022-02-01 Analysis of β-agonists in Different Biological Matrices By Liquid Chromatography–tandem Mass Spectrometry Śniegocki, Tomasz Sell, Bartosz Posyniak, Andrzej J Vet Res Review Article INTRODUCTION: Wide use is made of β-agonists in therapy due to their smooth muscle–relaxant properties. They also have a side effect of increasing muscle mass. Besides improving oxygen utilisation as bronchodilators, β-agonists increase protein synthesis and promote fat burning. The growth- and performance-enhancing effects are often exploited in illegal use. The guiding objective of this study was to develop a procedure for the determination of β-agonists by a single method in different types of matrices. MATERIAL AND METHODS: Five grams of homogenised samples were subjected to enzymatic hydrolysis with β-glucuronidase in ammonium acetate, pH 5.2. Purification was performed by solid phase extraction. Analytes were eluted with 10% acetic acid in methanol. The eluted β-agonists were analysed by high-performance liquid chromatography–tandem mass spectrometry. RESULTS: Validation results met the requirement of the confirmation criteria according to European Commission Decision 2002/657/EC in terms of apparent recoveries (93.2–112.0%), repeatability (3.1–7.1%) and intra-laboratory reproducibility (4.1–8.2%). CONCLUSION: The method can be successfully applied in the detection and determination of clenbuterol, salbutamol, mabuterol, mapenterol, terbutaline, brombuterol, zilpaterol, isoxsuprine and ractopamine in feed, drinking water, urine, muscle, lung and liver matrices. Sciendo 2021-11-20 /pmc/articles/PMC8775736/ /pubmed/35112001 http://dx.doi.org/10.2478/jvetres-2021-0058 Text en © 2021 T. Śniegocki et al. published by Sciendo https://creativecommons.org/licenses/by-nc-nd/3.0/This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
spellingShingle Review Article
Śniegocki, Tomasz
Sell, Bartosz
Posyniak, Andrzej
Analysis of β-agonists in Different Biological Matrices By Liquid Chromatography–tandem Mass Spectrometry
title Analysis of β-agonists in Different Biological Matrices By Liquid Chromatography–tandem Mass Spectrometry
title_full Analysis of β-agonists in Different Biological Matrices By Liquid Chromatography–tandem Mass Spectrometry
title_fullStr Analysis of β-agonists in Different Biological Matrices By Liquid Chromatography–tandem Mass Spectrometry
title_full_unstemmed Analysis of β-agonists in Different Biological Matrices By Liquid Chromatography–tandem Mass Spectrometry
title_short Analysis of β-agonists in Different Biological Matrices By Liquid Chromatography–tandem Mass Spectrometry
title_sort analysis of β-agonists in different biological matrices by liquid chromatography–tandem mass spectrometry
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775736/
https://www.ncbi.nlm.nih.gov/pubmed/35112001
http://dx.doi.org/10.2478/jvetres-2021-0058
work_keys_str_mv AT sniegockitomasz analysisofbagonistsindifferentbiologicalmatricesbyliquidchromatographytandemmassspectrometry
AT sellbartosz analysisofbagonistsindifferentbiologicalmatricesbyliquidchromatographytandemmassspectrometry
AT posyniakandrzej analysisofbagonistsindifferentbiologicalmatricesbyliquidchromatographytandemmassspectrometry